Novo Nordisk US Operations EVP Jamey Millar Statement (July 1): Wegovy Access Expanded for Medicare Beneficiaries Through the Bridge; All Doses and Formulations of Wegovy Injection and Wegovy Pill Available Nationwide, Company Flags Cardiovascular-Outcome Evidence as Distinguishing Feature for Seniors 65+ with Known Heart Disease
Novo Nordisk US Operations EVP Jamey Millar released a formal statement Wednesday July 1, 2026, framing the Medicare GLP-1 Bridge as 'an important step in getting Wegovy to more patients' and committing to continued work with CMS, healthcare professionals, pharmacists, and patient advocates on Bridge implementation. Millar's cardiovascular-outcome framing was the piece of the statement designed to distinguish Wegovy from competitor GLP-1s under the Bridge: 'Obesity is a serious, common chronic disease facing older Americans, and Wegovy is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions.' The SELECT trial data (2023-2024) underpin the cardiovascular claim. The Bridge covers all doses and formulations of Wegovy injection (including the 7.2 mg Wegovy HD launched April 2026) and Wegovy pill (1.5, 4, 9, and 25 mg oral tablets, launched January 5, 2026 and reaching 3 million prescriptions by June 7). The program is available nationwide across all US states and territories through December 31, 2027. PharmExec and PR Newswire ran the announcement.